XNAS · Healthcare · Biotechnology
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | Q1 2026 | -1.79 | -1.69 | +5.59% | $20.7M | ✅ Beat | +4.31% | -3.81% | +4.81% |
| 2026-02-12 | Q4 2025 | -1.96 | -1.86 | +5.10% | $20.0M | ✅ Beat | +3.03% | +1.82% | -0.78% |
| 2025-10-30 |
| Q3 2025 |
| -1.92 |
| -1.78 |
| +7.29% |
| $12.9M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-31 | Q2 2025 | -1.77 | -1.93 | -9.04% | $12.5M | ❌ Miss | -1.70% | -0.43% | +1.32% |
| 2025-05-01 | Q1 2025 | -1.76 | -1.55 | +11.93% | $8.7M | ✅ Beat | -2.71% | -9.37% | +5.46% |
| 2025-02-13 | Q4 2024 | -1.63 | -1.94 | -19.02% | $10.7M | ❌ Miss | -0.24% | +1.35% | -3.93% |
| 2024-10-31 | Q3 2024 | 1.11 | -1.43 | -228.83% | $9.0M | ❌ Miss | +0.99% | +23.97% | +32.50% |
| 2024-08-01 | Q2 2024 | -1.59 | -1.69 | -6.29% | $8.6M | ❌ Miss | -1.21% | -1.60% | +0.52% |
Showing last 8 quarters.